Published in J Med Chem on March 10, 2017
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev (2001) 36.00
Crystal structure of rhodopsin: A G protein-coupled receptor. Science (2000) 28.60
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 26.19
High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science (2007) 20.32
ZINC--a free database of commercially available compounds for virtual screening. J Chem Inf Model (2005) 16.75
Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature (2011) 13.92
Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science (2010) 10.30
Structure of a nanobody-stabilized active state of the β(2) adrenoceptor. Nature (2011) 9.61
International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev (2000) 7.17
New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem (2010) 6.54
Extended-connectivity fingerprints. J Chem Inf Model (2010) 5.50
Molecular signatures of G-protein-coupled receptors. Nature (2013) 5.19
Global mapping of pharmacological space. Nat Biotechnol (2006) 4.99
A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A (1999) 4.46
The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol (2004) 4.09
Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J (1997) 4.04
Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett (2002) 3.56
Principles and applications of halogen bonding in medicinal chemistry and chemical biology. J Med Chem (2013) 3.48
A 'rule of three' for fragment-based lead discovery? Drug Discov Today (2003) 3.45
Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol (2007) 3.43
Structural basis for allosteric regulation of GPCRs by sodium ions. Science (2012) 3.40
GPCRDB information system for G protein-coupled receptors. Nucleic Acids Res (2003) 3.34
Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science (2013) 3.17
Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature (2013) 2.49
Structure-based discovery of beta2-adrenergic receptor ligands. Proc Natl Acad Sci U S A (2009) 2.48
Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser. Nature (2015) 2.43
Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J Virol (1998) 2.38
Human cytomegalovirus open reading frame US28 encodes a functional beta chemokine receptor. J Biol Chem (1994) 2.34
Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12. Sci Signal (2008) 2.33
Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol (1999) 2.23
Structure of active β-arrestin-1 bound to a G-protein-coupled receptor phosphopeptide. Nature (2013) 2.14
Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go. Br J Pharmacol (2007) 2.13
Status of GPCR modeling and docking as reflected by community-wide GPCR Dock 2010 assessment. Structure (2011) 2.11
Ligand discovery from a dopamine D3 receptor homology model and crystal structure. Nat Chem Biol (2011) 2.10
Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities. J Biol Chem (2000) 2.07
Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J Biol Chem (2001) 2.00
Protein-based virtual screening of chemical databases. II. Are homology models of G-Protein Coupled Receptors suitable targets? Proteins (2003) 1.93
Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem (2010) 1.88
Structure of the adenosine A(2A) receptor bound to an engineered G protein. Nature (2016) 1.84
G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol Rev (2014) 1.82
Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol (2007) 1.77
HCMV-encoded chemokine receptor US28 mediates proliferative signaling through the IL-6-STAT3 axis. Sci Signal (2010) 1.72
Structure-based discovery of A2A adenosine receptor ligands. J Med Chem (2010) 1.71
Extra-helical binding site of a glucagon receptor antagonist. Nature (2016) 1.65
Structural biology. Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine. Science (2015) 1.65
Discovery of 1,2,4-triazine derivatives as adenosine A(2A) antagonists using structure based drug design. J Med Chem (2012) 1.60
A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J Biol Chem (2002) 1.59
Selective structure-based virtual screening for full and partial agonists of the beta2 adrenergic receptor. J Med Chem (2008) 1.59
Structural and functional basis of CXCL12 (stromal cell-derived factor-1 alpha) binding to heparin. J Biol Chem (2007) 1.58
Structural basis of receptor sulfotyrosine recognition by a CC chemokine: the N-terminal region of CCR3 bound to CCL11/eotaxin-1. Structure (2014) 1.58
Crystal structure of chemically synthesized [N33A] stromal cell-derived factor 1alpha, a potent ligand for the HIV-1 "fusin" coreceptor. Proc Natl Acad Sci U S A (1998) 1.58
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression. J Med Chem (2006) 1.58
Structural and molecular interactions of CCR5 inhibitors with CCR5. J Biol Chem (2006) 1.55
The structure of human macrophage inflammatory protein-3alpha /CCL20. Linking antimicrobial and CC chemokine receptor-6-binding activities with human beta-defensins. J Biol Chem (2002) 1.53
Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor. J Biol Chem (2003) 1.50
The cytomegalovirus-encoded chemokine receptor US28 promotes intestinal neoplasia in transgenic mice. J Clin Invest (2010) 1.50
Structure of a CXC chemokine-receptor fragment in complex with interleukin-8. Structure (1999) 1.47
Contribution of conformer focusing to the uncertainty in predicting free energies for protein-ligand binding. J Med Chem (2006) 1.46
G protein-coupled receptors: in silico drug discovery in 3D. Proc Natl Acad Sci U S A (2004) 1.43
The X-ray structure of RANTES: heparin-derived disaccharides allows the rational design of chemokine inhibitors. Structure (2004) 1.42
CXCR3 requires tyrosine sulfation for ligand binding and a second extracellular loop arginine residue for ligand-induced chemotaxis. Mol Cell Biol (2006) 1.42
Pharmacological modulation of chemokine receptor function. Br J Pharmacol (2012) 1.41
Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. J Med Chem (2005) 1.41
Structural biology. Structural basis for chemokine recognition and activation of a viral G protein-coupled receptor. Science (2015) 1.40
Metal ion enhanced binding of AMD3100 to Asp262 in the CXCR4 receptor. Biochemistry (2003) 1.40
Both 5-arylidene-2-thioxodihydropyrimidine-4,6(1H,5H)-diones and 3-thioxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-ones are light-dependent tumor necrosis factor-alpha antagonists. Bioorg Med Chem Lett (2003) 1.39
Structural and functional characterization of human CXCR4 as a chemokine receptor and HIV-1 co-receptor by mutagenesis and molecular modeling studies. J Biol Chem (2001) 1.38
Proton NMR assignments and solution conformation of RANTES, a chemokine of the C-C type. Biochemistry (1995) 1.38
The TXP motif in the second transmembrane helix of CCR5. A structural determinant of chemokine-induced activation. J Biol Chem (2001) 1.37
Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 Env protein. J Biol Chem (1999) 1.36
In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proc Natl Acad Sci U S A (2008) 1.34
Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. J Med Chem (2011) 1.30
Partial functional mapping of the human interleukin-8 type A receptor. Identification of a major ligand binding domain. J Biol Chem (1993) 1.30
Maraviroc: a review of its use in HIV infection and beyond. Drug Des Devel Ther (2015) 1.29
GPCR structure-based virtual screening approach for CB2 antagonist search. J Chem Inf Model (2007) 1.28
New insights from structural biology into the druggability of G protein-coupled receptors. Trends Pharmacol Sci (2012) 1.26
Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5). J Biol Chem (2011) 1.25
Two disparate ligand-binding sites in the human P2Y1 receptor. Nature (2015) 1.25
Structure-based ligand discovery for the protein-protein interface of chemokine receptor CXCR4. Proc Natl Acad Sci U S A (2012) 1.25
A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for Ligands and Proteins (FLAP): theory and application. J Chem Inf Model (2007) 1.24
Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation. J Biol Chem (2006) 1.24
Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening. J Med Chem (2007) 1.23
Molecular modeling of the second extracellular loop of G-protein coupled receptors and its implication on structure-based virtual screening. Proteins (2008) 1.20
Generic GPCR residue numbers - aligning topology maps while minding the gaps. Trends Pharmacol Sci (2014) 1.19
Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo. J Med Chem (2008) 1.19
High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. Nature (2014) 1.19
Distinct functional sites for human immunodeficiency virus type 1 and stromal cell-derived factor 1alpha on CXCR4 transmembrane helical domains. J Virol (2005) 1.18
Complete mutagenesis of the extracellular domain of interleukin-8 (IL-8) type A receptor identifies charged residues mediating IL-8 binding and signal transduction. J Biol Chem (1994) 1.15
Crystal structure of recombinant native SDF-1alpha with additional mutagenesis studies: an attempt at a more comprehensive interpretation of accumulated structure-activity relationship data. J Interferon Cytokine Res (2000) 1.15
Modeling the structural basis of human CCR5 chemokine receptor function: from homology model building and molecular dynamics validation to agonist and antagonist docking. J Chem Inf Model (2006) 1.14
Unique ligand binding sites on CXCR4 probed by a chemical biology approach: implications for the design of selective human immunodeficiency virus type 1 inhibitors. J Virol (2005) 1.14
Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors. Mol Pharmacol (2008) 1.13
Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists. Nature (2016) 1.13
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor. J Biol Chem (2007) 1.13
Activation of CCR5 by chemokines involves an aromatic cluster between transmembrane helices 2 and 3. J Biol Chem (2002) 1.13
Discovery of small molecule CXCR4 antagonists. J Med Chem (2007) 1.12
GPCRdb: an information system for G protein-coupled receptors. Nucleic Acids Res (2015) 1.12
CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc Natl Acad Sci U S A (2010) 1.11
Identification of novel adenosine A(2A) receptor antagonists by virtual screening. J Med Chem (2012) 1.10